These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1056 related items for PubMed ID: 26382221

  • 1. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H, Imai S, Harada K, Fujisawa M.
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW.
    Zhonghua Zhong Liu Za Zhi; 2018 May 23; 40(5):384-389. PubMed ID: 29860767
    [Abstract] [Full Text] [Related]

  • 3. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R, Palazzo A, Trenta P, Mezi S, Pellegrino D, Naso G, Cortesi E.
    Am J Clin Oncol; 2014 Dec 23; 37(6):611-5. PubMed ID: 23388560
    [Abstract] [Full Text] [Related]

  • 4. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI.
    Lancet Oncol; 2013 May 23; 14(6):552-62. PubMed ID: 23598172
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ.
    Lancet Oncol; 2013 Dec 23; 14(13):1287-94. PubMed ID: 24206640
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
    Sikic D, Lüdecke G, Lieb V, Keck B.
    Urologe A; 2016 May 23; 55(5):648-52. PubMed ID: 27119958
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
    Rudresha AH, Chaudhuri T, Lakshmaiah KC, Babu GK, Lokanatha D, Jacob LA, Suresh Babu MC, Lokesh KN, Rajeev LK.
    Indian J Cancer; 2017 May 23; 54(4):626-630. PubMed ID: 30082547
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.
    Curr Med Res Opin; 2016 May 23; 32(4):741-7. PubMed ID: 26744781
    [Abstract] [Full Text] [Related]

  • 13. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V.
    Eur Urol; 2009 Jun 23; 55(6):1430-8. PubMed ID: 18950936
    [Abstract] [Full Text] [Related]

  • 14. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA, Balagamwala EH, Angelov L, Suh JH, Rini B, Garcia JA, Ahluwalia M, Chao ST.
    J Neurosurg Spine; 2016 Dec 23; 25(6):766-774. PubMed ID: 27391397
    [Abstract] [Full Text] [Related]

  • 15. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A, Miyake H, Harada K, Fujisawa M.
    Anticancer Res; 2015 May 23; 35(5):3067-73. PubMed ID: 25964597
    [Abstract] [Full Text] [Related]

  • 16. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK.
    Clin Genitourin Cancer; 2017 Dec 23; 15(6):724-732. PubMed ID: 28645482
    [Abstract] [Full Text] [Related]

  • 17. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    Ishihara H, Yagisawa T, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K.
    Int J Clin Oncol; 2017 Feb 23; 22(1):126-135. PubMed ID: 27549785
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.